bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
090-10-1080-01

Order Name:
Heparin-induced PF4 Antibody

 
Useful For:
Detection of IgG antibodies directed against heparin/platelet factor 4 complexes that are implicated in the pathogenesis of immune-mediated type II heparin-induced thrombocytopenia (HIT-II).
 
Methodology:
latex-enhanced immunoturbidimetric assay
 
AliasesName:
Heparin Induced Antibody
Heparin-Dependent Antibody
HIT
PF4
 
 
 
Test Code:
090-10-1080-01

Order Name:
Heparin-induced PF4 Antibody

 
Patient Preparation:
Samples should not be taken from patients receiving unfractionated heparin until at least 2 hours following the last administration.
 
Collection Specimen Or Container:
Blood/ Sodium citrate tube (Sodium Citrate 3.2% anticoagulant, Blue top) 3 mL, 1 tube
 
Specimen Testing Type:
Citrate plasma, minimum volume 0.5 mL
 
Sub Mission Container:
Plastic tube
 
Rejection Criteria:
Hemolysis: Hemoglobin >495 mg/dL will be reject.
Lipemia: Triglyceride >375 mg/dL will be reject.
Icterus: Bilirubin >18 mg/dL will be rejected.
Other:
  1. Clotted specimen will be rejected.
  2. Rheumatoid factor >1,000 IU/mL will be reject
 
Specimen Stabillity:
Specimen Type Temperature Time
Plasma, Sodium citrate Refrigerated, 2oC to 8oC 4 hours
Frozen, -20oC 2 weeks
 
 
 
Test Code:
090-10-1080-01

Order Name:
Heparin-induced PF4 Antibody

 
Method detail:
latex-enhanced immunoturbidimetric assay
 
Schedule:
Tested Daily (24 hours)
 
Turnaround Time:
Collected specimen to report within 2 hours
 
Performing Location:
Hematology, Laboratory Department, Tel. 17254
 
Specimen Retention Time:
14 days
 
 
 
Test Code:
090-10-1080-01

Order Name:
Heparin-induced PF4 Antibody

 
 
Clinical Information:
Heparin-induced thrombocytopenia (HIT) is an immune complex mediated disorder that can cause morbidity and mortality in patients receiving heparin therapy

HIT is considered a paradoxical disease in that anticoagulant is administered to prevent thrombosis; however the major clinical event in HIT is an increased risk for venous and/or arterial thrombosis

HIT is suspected when patients treated with unfractionated heparin (UFH) or low molecular weight heparin (LMWH) show a decrease of platelet counts greater than 50% from baseline, typically
between day 5 and 10 from the initiation of the anticoagulant treatment.  Cases of early-onset HIT and delayed-onset HIT have also been reported. Prompt diagnosis is very important because heparin treatment must be suspended and alternative anticoagulants used in case of confirmed HIT

Type II HIT, the immunoallergic type, is caused by the development of platelet-activating antibodies, mostly directed against Platelet Factor 4 when complexed with Heparin (PF4/H). These antibodies are the primary cause for inducing thrombosis both venous and arteria

PF4/H antibody testing combined with an appropriate clinical assessment has been proven to be very useful as an aid in the management of HIT suspected patients. Particularly, a negative result for a PF4/H antibody test can support the clinical decision to exclude the presence of HIT, and therefore continue heparin treatment. A weak positivity for PF4 antibodies may indicate that the antibodies are non-platelet activating, while a strong positivity may indicate a higher risk for HIT. In both cases, confirmation with a functional test is recommended. A clinical reassessment supported by laboratory data should be performed before confirmation or exclusion of the diagnosis.
 
Reference Value:
Less than 1 U/mL
 
Clinical Reference:
  1. Manufacturer’s reagent Package Insert, HIT- Ab(PF4-H) HemosIL®, Instrumentation Laboratory Company - Bedford, MA 01730-2443 (USA), Instrumentation Laboratory SpA - V.le Monza 338 - 20128 Milano (Italy), 11/2014
  2. https://www.mayocliniclabs.com (Retrieved: 22 Jan 2019)